Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis

Molecular characterization of Philadelphia chromosome-negative (Ph−) chronic myeloproliferative disorders, such as systemic mastocytosis (SM), has provided a clear rationale for investigating novel targeted therapies. The tyrosine kinase (TK) inhibitor dasatinib is 325-fold more potent against Bcr-A...

Full description

Saved in:
Bibliographic Details
Published in:Clin Cancer Res
Main Authors: Verstovsek, Srdan, Tefferi, Ayalew, Cortes, Jorge, O’Brien, Susan, Garcia-Manero, Guillermo, Pardanani, Animesh, Akin, Cem, Faderl, Stefan, Manshouri, Taghi, Thomas, Deborah, Kantarjian, Hagop
Format: Artigo
Language:Inglês
Published: 2008
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5018899/
https://ncbi.nlm.nih.gov/pubmed/18559612
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-08-0366
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items